Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 990 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
独立董事候选人关于参加最近一次独立董事培训的书面承诺
Regulatory Filings Classification · 57% confidence The document is a written commitment by an independent director candidate to attend required training and obtain certification, as mandated by the exchange. It is not announcing financial results, an AGM presentation, an actual director change, or any transaction. It is a compliance-related filing falling under miscellaneous regulatory announcements. Therefore it is classified as a generic Regulatory Filing (RNS).
2026-05-15 Chinese
关于独立董事任期届满辞职暨补选独立董事的公告
Board/Management Information Classification · 90% confidence The document is an official announcement titled “关于独立董事任期届满辞职暨补选独立董事的公告,” describing the resignation of an independent director upon term expiration and the board’s plan to nominate and elect a replacement independent director. It discusses changes to the board composition and director appointments. This matches the Board/Management Information category (MANG).
2026-05-15 Chinese
关于调整2026年员工持股计划购买价格的公告
Share Issue/Capital Change Classification · 75% confidence The document is an official announcement by the company’s board regarding an adjustment to the 2026 employee share ownership plan’s purchase price. It relates to changes in the terms of a planned share issue (employee stock plan) rather than financial results or a general regulatory filing. This falls under Share Issue/Capital Change activities (new share issues or capital structure changes).
2026-05-15 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company’s fourth board of directors meeting (e.g., election of an independent director candidate, approval of employee share plan pricing, and proposal to convene a shareholders’ meeting). It does not contain full financial statements, earnings data, or substantive regulatory filings but rather board decisions and management changes, matching the definition of Board/Management Information.
2026-05-15 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 82% confidence The document is a corporate announcement by Zhejiang Tailin Biotech (证券代码300813) detailing the award of 5 patent certificates, approved by the board, with no financial data or reference to a report being published. This is a regulatory announcement of patent acquisitions and does not fit any specific report category (e.g., earnings, AGM materials, financing, etc.), so it falls under the general Regulatory Filings (RNS) category.
2026-05-11 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm (Grandall Law Firm) regarding Zhejiang Tailin Biotechnology Co., Ltd.'s issuance of convertible corporate bonds to unspecified investors. It extensively references Chinese securities laws, company laws, regulatory rules, and audit reports. The document includes detailed legal analysis, verification of the issuer's qualifications, compliance with issuance conditions, and legal opinions on the issuance process. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital market transaction (issuance of convertible bonds). This type of document is best classified under Capital/Financing Update (CAP) as it pertains to updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is the full legal opinion, not just an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2026-04-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.